This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Short interest: 18%
52-week high: $4.02
Current price: $2.28
Year-to-date performance relative to the Nasdaq Biotechnology Index: Up 39%
Shorts believe BioSante's Libigel is nothing more than a me-too, low-dose formulation of testosterone being developed for the disease-mongering indication of female sexual dysfunction. A female Viagra this isn't, which is why deep-pocketed Big Pharma is steering clear.
>>To see these stocks in action, visit the
10 Most Shorted Stocks in Biotech portfolio on Stockpickr.
--Written by Adam Feuerstein in Boston.